Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA’s Greatest Biosimilar Impact May Be Interchangeability Policy, Sandoz Says

May 09 2012

• By Derrick Gingery

Related Content

Biosimilars Pathway Dilemma: When Should Sponsors Pick (k) Before (a)?

May 23 2011

User Fee Legislation Revs Through Senate Mark-up, But House Bill Goes Back Into The Shop

Apr 30 2012

Biosimilar Interchangeability: Stakeholders Want More FDA Guidance, Fewer Hurdles

Apr 30 2012

On The Trail Of Biosimilar Disclosure Scofflaws: FTC To Watch For Anti-Competitive Issues

May 07 2012

PDUFA Stars Aligning As House Draft Gives FDA Direct Authority Over Importers

May 07 2012

Biosimilars May Drift, But What Should FDA Do About It?

Nov 15 2010

Related Companies

Novartis AG

Additional Topics

United States Europe Drug Approval Standards BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window